GSK plc announced that the European Medicines Agency has accepted their treatment, bepirovirsen, for review as a potential first-in-class therapy for chronic hepatitis B, supported by significant clinical trial results. This was reported on March 27, 2026, and nearly 3.2 million people in Europe are affected by this condition.